Sunitinib versus interferon-[alpha] in metastatic RCC
Sunitinib versus interferon-[alpha] in metastatic RCC
About this item
Full title
Author / Creator
Publisher
Nature Publishing Group
Journal title
Language
English
Formats
Publication information
Publisher
Nature Publishing Group
Subjects
More information
Scope and Contents
Contents
Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-[alpha] as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line t...
Alternative Titles
Full title
Sunitinib versus interferon-[alpha] in metastatic RCC
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracacademiconefile_A216040474
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracacademiconefile_A216040474
Other Identifiers
ISSN
1759-4774
DOI
10.1038/nrclinonc.2009.173
